1. Home
  2. COOK vs CGEN Comparison

COOK vs CGEN Comparison

Compare COOK & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Traeger Inc.

COOK

Traeger Inc.

HOLD

Current Price

$50.82

Market Cap

170.4M

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$2.48

Market Cap

191.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COOK
CGEN
Founded
1985
1993
Country
United States
Israel
Employees
N/A
N/A
Industry
Wholesale Distributors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
170.4M
191.1M
IPO Year
2021
2001

Fundamental Metrics

Financial Performance
Metric
COOK
CGEN
Price
$50.82
$2.48
Analyst Decision
Hold
Strong Buy
Analyst Count
5
2
Target Price
$53.00
$5.00
AVG Volume (30 Days)
26.5K
300.4K
Earning Date
05-11-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$559,520,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.07
$75.09
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$1.30
52 Week High
$86.59
$3.24

Technical Indicators

Market Signals
Indicator
COOK
CGEN
Relative Strength Index (RSI) 34.89 47.71
Support Level $39.02 $2.23
Resistance Level $77.25 $2.54
Average True Range (ATR) 2.62 0.13
MACD -0.28 -0.02
Stochastic Oscillator 30.17 6.32

Price Performance

Historical Comparison
COOK
CGEN

About COOK Traeger Inc.

Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

Share on Social Networks: